

 Open access • Posted Content • DOI:10.1101/2020.08.17.254201

Structure of the extracellular region of the bacterial type VIIb secretion system subunit EsaA — [Source link](#)

Timothy A. Klein, Dirk W. Grebenc, Shil Y. Gandhi, Vraj S. Shah ...+2 more authors

Institutions: McMaster University, Argonne National Laboratory

Published on: 17 Aug 2020 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Effector, Secretion, Cell envelope, Peptidoglycan and Protein subunit

Related papers:

- [Structure of the Extracellular Region of the Bacterial Type VIIb Secretion System Subunit EsaA.](#)
- [Timing is everything: the regulation of type III secretion](#)
- [Anchoring the type VI secretion system to the peptidoglycan: TssL, TagL, TagP... what else?](#)
- [On the path to uncover the bacterial type II secretion system.](#)
- [Mechanism and structure of the bacterial type IV secretion systems.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/structure-of-the-extracellular-region-of-the-bacterial-type-2qowvruesl>

1
2 **Structure of the extracellular region of the bacterial type VIIb secretion**
3 **system subunit EsaA**

4
5 Timothy A. Klein,^{1,2} Dirk W. Grebenc,^{1,2} Shil Y. Gandhi,^{1,2} Vraj S. Shah,^{1,2} Youngchang Kim,³
6 and John C. Whitney^{1,2,4*}

7
8
9
10 ¹Michael DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON,
11 L8S 4K1, Canada

12 ²Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON,
13 L8S 4K1, Canada

14 ³Structural Biology Center, X-ray Science, Argonne National Laboratory, Argonne, Illinois,
15 USA

16 ⁴David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, ON, L8S 4K1,
17 Canada

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 * To whom correspondence should be addressed: J.C.W.
36 Email – jwhitney@mcmaster.ca
37 Telephone – (+1) 905-525-9140
38

39 **Running title:** Structure of EsaA
40
41

42 **Summary**

43 Gram-positive bacteria use type VII secretion systems (T7SSs) to export effector proteins that
44 manipulate the physiology of nearby prokaryotic and eukaryotic cells. Several mycobacterial
45 T7SSs have established roles in virulence. By contrast, recent work has demonstrated that the
46 genetically distinct T7SSb pathway found in Firmicutes bacteria more often functions to mediate
47 interbacterial competition. A lack of structural information on the T7SSb has limited the
48 understanding of effector export by this protein secretion apparatus. In this work, we present the
49 2.4Å crystal structure of the extracellular region of the elusive T7SSb subunit EsaA from
50 *Streptococcus gallolyticus*. Our structure reveals that homodimeric EsaA is an elongated, arrow-
51 shaped protein with a surface-accessible ‘tip’, which serves as a receptor for lytic bacteriophages
52 in some species of bacteria. Because it is the only T7SSb subunit large enough to traverse the
53 thick peptidoglycan layer of Firmicutes bacteria, we propose that EsaA plays a critical role in
54 transporting effectors across the entirety of the Gram-positive cell envelope.

55

56

57 Introduction

58 Protein secretion is a critical aspect of bacterial physiology and requires the use of
59 membrane-embedded secretion apparatuses. In addition to the general secretory pathway and the
60 twin-arginine translocase, many species of Gram-positive bacteria use type VII secretion systems
61 (T7SSs) for protein export (Abdallah et al., 2007). T7SSs are used by bacteria belonging to the
62 phyla Actinobacteria and Firmicutes and are divided into T7SSa and T7SSb. This distinction
63 reflects differences in T7SS subunit composition between these two distantly related groups of
64 Gram-positive bacteria (Klein et al., 2020). The T7SSa was originally discovered in
65 *Mycobacterium tuberculosis* where it acts as a virulence factor that facilitates immune evasion
66 and phagosomal escape during infection, whereas the T7SSb was initially characterized in
67 *Staphylococcus aureus* and has been shown to play a dual role in pathogenesis and interbacterial
68 competition (Cao et al., 2016; Gao et al., 2004; Ohr et al., 2017; Ulhuq et al., 2020). The
69 interkingdom-targeting capability of the T7SSb has also been demonstrated in the opportunistic
70 pathogen *Streptococcus intermedius* with the antibacterial activity being attributed to the NAD⁺
71 hydrolase effector TelB and the cell wall precursor degrading effector TelC (Hasegawa et al.,
72 2017; Klein et al., 2018; Whitney et al., 2017). The T7SSb pathways of *Bacillus subtilis* and
73 *Enterococcus faecalis* were also recently shown to antagonize competitor bacteria (Tassinari et
74 al., 2020; Chatterjee et al., 2020).

75 Much of our current understanding of the T7SS has resulted from studies on effector
76 function, which can often explain the phenotypes associated with a given T7SS pathway. Less
77 well understood is the mechanism of T7SS effector export across the cell envelope. Recent
78 structural analyses have begun to elucidate the ultrastructure of T7SS apparatuses and provide
79 clues as to how this secretion apparatus facilitates protein export (Famelis et al., 2019; Poweleit
80 et al., 2019; Rosenberg et al., 2015). However, these studies have largely focused on T7SSa
81 apparatuses. Of the four major structural proteins that make up the T7SSa, only the
82 EccC/EssC/YukB ATPase is conserved in T7SSb systems. The other three T7SSa subunits,
83 EccB, EccD, and EccE, possess no sequence homology to the EssA, EssB, and EsaA
84 components of the T7SSb and consequently, the two systems likely form distinct structures that
85 may not share a common mechanism for protein export.

86 EsaA is perhaps the least understood of the T7SSb structural components. Transposon
87 mutagenesis in *S. aureus* initially suggested that EsaA was dispensable for effector secretion but
88 subsequent characterization showed that this subunit is likely essential for T7SSb-dependent

89 protein export (Burts et al., 2005; Kneuper et al., 2014). No structural data exists for EsaA, but
90 analysis of its membrane topology suggests it consists of a large soluble region flanked by N-
91 and C-terminal transmembrane domains (TMDs) (Ahmed et al., 2018; Mietrach et al., 2019).
92 Proteomic analyses of intact *S. aureus* cells has shown that EsaA is surface exposed and that its
93 soluble domain may extend into the extracellular milieu (Dreisbach et al., 2010). Furthermore,
94 studies in *B. subtilis* have shown that the EsaA homologue YueB is the cell surface receptor for
95 the SPP1 bacteriophage (Sao-Jose et al., 2004; Sao-Jose et al., 2006). Similarly, many strains of
96 *E. faecalis* possess the EsaA paralogue Phage Infection Protein (PIP), which serves as a receptor
97 for Enterococcal phage (Duerkop et al., 2016). The prediction that EsaA extends from the plasma
98 membrane to the cell surface make it unique among the T7SSb subunits because the other
99 structural proteins have either extracellular domains that are too small to span the estimated 30-
100 50 nm thick peptidoglycan layer of Firmicutes bacteria or are entirely intracellular (Tassinari et
101 al., 2020; Vollmer et al., 2008).

102 In this study, we present the first crystal structure of the extracellular domain of EsaA,
103 revealing a novel protein fold characterized by a highly elongated, arrow-shaped homodimer
104 comprised of three distinct domains. Using cysteine cross-linking, we show that EsaA dimers
105 occur *in vivo* and propose that upon multimerization with the other subunits of the T7SSb, form a
106 conduit that facilitates effector export across the cell envelope of Gram-positive bacteria.

107

108 **Results**

109 **EsaA is required for the secretion of EsxA and Tel effector proteins from *S. intermedius***

110 Given the conflicting reports on the essentiality of EsaA for T7S, we first examined the
111 consequences of inactivating *esaA* on effector export using the model T7SSb bacterium *S.*
112 *intermedius*. Characterized T7SSb systems export two major families of effectors: small, alpha-
113 helical WXG100 proteins whose precise function is unknown; and large, multi-domain LXG
114 proteins that possess C-terminal toxin domains. *S. intermedius* strain B196 exports a single
115 WXG100 effector, EsxA, and the three LXG effectors TelA, TelB and TelC (Whitney et al.,
116 2017). Consistent with functioning as a core structural subunit of the T7SSb apparatus, we found
117 that replacement of the *esaA* gene with a kanamycin resistance cassette yielded a *S. intermedius*
118 strain that was no longer able to export detectable levels of EsxA and TelC into culture
119 supernatants (Figure 1A). Similarly, supernatant NADase activity, which is indicative of TelB

120 secretion, was reduced to levels comparable to that of a T7SSb-inactivated strain, Δ *essC*. (Figure
121 1B). Importantly, we found that export of EsxA and TelC, as well as TelB-dependent NADase
122 activity could be restored by plasmid-based expression of EsaA indicating that our allelic
123 replacement approach did not affect the expression of genes encoding other structural subunits of
124 the T7SSb, which are part of a five-gene cluster that also contains *esaA*. Together, these data
125 indicate that *esaA* is required for WXG100 and LXG effector export in *S. intermedius*.

126

127 **Topology mapping of EsaA reveals a large extracellular domain**

128 We next sought to examine the membrane topology of *S. intermedius* EsaA (*SiEsaA*).
129 Though cell surface proteomics conducted on *S. aureus* suggest that the soluble region of EsaA
130 exists extracellularly, this assertion has not been tested directly for any T7SSb-containing
131 bacterium. Furthermore, the number of putative TMDs differs among EsaA homologues with
132 *SiEsaA* having a single predicted TMD on either side of its soluble region whereas EsaA proteins
133 from *S. aureus*, *E. faecalis*, *B. subtilis*, *Bacillus cereus* and *Listeria monocytogenes* possess five
134 TMDs at their C-terminus (Figure S1).

135 After confirming that *SiEsaA* localizes to the membrane fraction of lysed *S. intermedius*
136 cells (Figure 2A), we introduced a series of cysteine point mutations spaced approximately 150
137 amino acids apart within *SiEsaA* to map its membrane topology using a cysteine-reactive
138 maleimide-conjugated fluorophore (Figure 2B). Plasmid-borne expression of each EsaA cysteine
139 mutant in our *esaA* deletion strain restored T7SSb-dependent export of TelC, demonstrating that
140 these mutations do not significantly affect EsaA function (Figure 2C). *SiEsaA* contains a single
141 native cysteine residue predicted to reside in its N-terminal TMD, and we found that with intact
142 cells this residue was inaccessible to the cysteine-reactive dye when analyzed by SDS-PAGE
143 (Figure 2D). Similarly, *SiEsaA* variants harboring cysteine mutations near the N- (V8C) or C-
144 terminus (F909C) of the protein did not react with the dye. By contrast, we found that cells
145 expressing *SiEsaA* bearing V150C, F302C, S454C or S605C mutations, all of which reside
146 within the predicted soluble region, yielded a prominent fluorescent band at the expected
147 molecular weight of *SiEsaA* (Figure 2D). A fluorescent band absent in the wild-type control was
148 also present in the V762C variant; however, this band migrates at a higher molecular weight than
149 *SiEsaA* making it difficult to interpret. Collectively, our data indicate that *SiEsaA* is a membrane
150 protein with a large extracellular domain and intracellular N- and C- termini.

151 **Structure determination of an extracellular fragment of EsaA**

152 Having mapped the membrane topology of *SiEsaA*, we next initiated structural studies on
153 the large extracellular fragment of the protein to gain more insight into its function. Although we
154 could readily express and purify a truncation of *SiEsaA* encompassing its entire extracellular
155 region (residues 41-871), this protein fragment had a propensity to degrade. To identify a stable
156 fragment of *SiEsaA* that would be more amenable to crystallization, we performed limited
157 proteolysis with chymotrypsin and isolated a protease-resistant species spanning residues 234-
158 790 (Figure S2). This fragment of *SiEsaA* crystallized readily but despite extensive optimization
159 efforts, diffraction quality crystals could not be obtained. Using the boundary information
160 obtained from our proteolysis experiments, we next tried a homologous EsaA fragment from
161 *Streptococcus gallolyticus* ATCC 43143 (*SgEsaA*₂₃₅₋₈₂₉), which has 42.9% pairwise sequence
162 identity to the equivalent region of *SiEsaA* (Figure 3A). Purified *SgEsaA*₂₃₅₋₈₂₉ formed
163 diffraction quality crystals and the 2.4Å structure of *SgEsaA*₂₃₅₋₈₂₉ was determined using
164 selenium-incorporated protein and the single-wavelength anomalous dispersion technique (Table
165 1). Interestingly, the resulting electron density map only yielded interpretable density for a model
166 encompassing residues 330-727 with an unmodeled gap from amino acids 514-554, suggesting
167 that large portions of EsaA are disordered in the crystal lattice. The final model was refined to a
168 $R_{\text{work}}/R_{\text{free}}$ of 0.21 and 0.26, respectively.

169

170 **EsaA forms an elongated, arrow-shaped dimer**

171 *SgEsaA*₂₃₅₋₈₂₉ forms a highly elongated structure comprised of two alpha helical domains
172 (AD-I and AD-II) and a beta-sheet domain (BD) (Figures 3B and 3C). The modelled fragment
173 adopts a ‘there and back again’ topology whereby the first half of *SgEsaA*₂₃₅₋₈₂₉ contributes
174 secondary structure elements to each of the three domains over a linear distance of 196Å.
175 Following a 180° turn that occurs within the unmodelled region between the $\beta 1$ and $\beta 2$ strands of
176 the beta-sheet domain, the C-terminal half of the protein similarly contributes secondary
177 structure to each domain with the C-terminus being located ~20Å away from the N-terminus at
178 the same pole (Figure 3B). In this arrangement, both the N- and C-terminal TMDs present in
179 full-length EsaA would be connected to the alpha helical AD-I domain. Given the orientation of
180 the termini, the directionality of the beta strands flanking the central unmodelled region, and the
181 number of unmodelled amino acids in our structure, it is likely that the length of the entire

182 extracellular region of EsaA is well in excess of the $\sim 200\text{\AA}$ measured for our model. This finding
183 provides a molecular explanation for how this protein is potentially able to traverse the
184 approximately 30-50nm thick cell wall of Firmicutes bacteria (Vollmer et al., 2008).

185 Another striking feature of SgEsaA₂₃₅₋₈₂₉ is that it adopts a head-to-head, belly-to-belly
186 homodimer that gives the protein its arrow-shaped appearance (Figure 3D). In this configuration,
187 all three domains and the intervening connecting regions contribute to the dimerization interface
188 (Figure 3E). Analysis of the dimer interface using the PDBePISA webserver indicates that dimer
189 formation is highly favorable (Δ^iG : -61.8kcal/mol) and generates 4436\AA^2 of buried surface area
190 (Krissinel and Henrick, 2007). Mapping EsaA sequence conservation onto our structure reveals
191 that the residues comprising the surface of EsaA are highly variable whereas the amino acids
192 involved in homodimerization show a much higher level of conservation (Figure 3F). The amino
193 acids lining the dimer interface are a mixture of hydrophobic, polar and acidic residues with
194 tyrosine, leucine, threonine and glutamate being the most abundant. We speculate that the large
195 surface area of the dimer interface combined with the abundance of hydrophobic residues
196 participating in homodimerization indicates that EsaA likely exists as an obligate homodimer
197 because solvent exposure of this surface in aqueous environments would bear a large entropic
198 cost.

199 A comparison of SgEsaA₂₃₅₋₈₂₉ to previously determined structures in the Protein Data
200 Bank using DALILITE revealed that the overall structure of SgEsaA₂₃₅₋₈₂₉ does not resemble
201 proteins of known structure (Holm, 2020). The top hit from this search was the BID domain of
202 the type IV secretion system (T4SS) effector protein Bep9 from *Bartonella clarridgeiae* (Z-
203 score, 8.5; C α root mean square deviation of 3.5\AA over 100 aligned residues), which only shares
204 structural similarity with AD-I of EsaA (Figure S3)(Stanger et al., 2017). BID domains comprise
205 one part of a bipartite signal sequence found in some T4SS effectors and thus appear unrelated in
206 terms of function. Based on these analyses, we conclude that EsaA adopts a novel protein fold.

207

208

209 **EsaA exists as dimer *in vitro* and *in vivo***

210 To test the biological significance of the EsaA homodimer observed in our crystal
211 structure, we examined a truncation of SgEsaA₂₃₅₋₈₂₉ that more accurately reflects the modeled
212 boundaries of our structure (SgEsaA₃₃₂₋₇₂₅) as well as the equivalent fragment of SiEsaA

213 (*SiEsaA*₃₂₈₋₆₈₅) by size exclusion chromatography coupled to multi-angle laser light scattering
214 (SEC-MALS). SEC-MALS allows for the accurate determination of protein molecular mass in
215 solution and therefore helps identify potentially artefactual oligomeric states induced by protein
216 crystallization. For both proteins, the major peak yielded a molecular mass consistent with dimer
217 formation and no evidence of *EsaA* monomers was observed in either case (Figure 4A and 4B).
218 The SEC-MALS analysis of *SgEsaA*₃₃₂₋₇₂₅ also revealed the presence of high molecular weight
219 aggregates but due to their heterogeneous nature and absence in the *SiEsaA*₃₂₈₋₆₈₅ sample, we
220 concluded that they likely do not represent biologically relevant assemblies of *EsaA*. In sum, the
221 extracellular fragment of *EsaA* exists as a dimer in solution.

222 We next wanted to examine if *EsaA* dimerizes *in vivo* in a manner that is consistent with
223 our crystal structure. To accomplish this, we inspected our *SgEsaA*₂₃₅₋₈₂₉ structure for amino acid
224 residues within the dimer interface that would be expected to crosslink if mutated to cysteine.
225 This analysis led to the identification of Thr628, found in in the linker region between the BD
226 and AD-II, Ala654, located within the AD-II, and Leu688, which exists in the linker region
227 between AD-I and AD-II (Figure 4C). We mutated each of these residues, along with the
228 equivalent residues in *SiEsaA* (Asn586, Thr612 and Leu644), to cysteine and examined the
229 ability of these variants to form covalent dimers. In support of the dimeric arrangement observed
230 in our crystal structure, all six variants formed β -mercaptoethanol (BME)-sensitive crosslinks
231 when the purified proteins were examined by SDS-PAGE (Figure 4D and 4E). Furthermore,
232 when we introduced the *SiEsaA* cysteine variants into our *S. intermedius* B196 *esaA* deletion
233 strain, BME-sensitive cysteine cross-links were observed in cells expressing either *EsaA*^{N586C} or
234 *EsaA*^{L644C} (Figure 4F). Collectively, our cross-linking data suggest that the structure of *SiEsaA* is
235 likely very similar to that of *SgEsaA* in terms of overall fold and dimeric arrangement, and that
236 dimeric *EsaA* represents a biologically relevant form of the protein.

237

238 **The structure of *EsaA* predicts the putative binding site for a bacteriophage receptor**

239 *EsaA* homologous proteins are not only involved in type VII secretion but have also been
240 shown to function as receptors for lytic bacteriophages (Sao-Jose et al., 2004). A recent analysis
241 of Enterococcal phages identified a 160 amino acid hypervariable region within the *EsaA*
242 homologous protein PIP (Phage Infection Protein) responsible for phage tropism among *E.*
243 *faecalis* strains (Duerkop et al., 2016). The topology of *EsaA* combined with the domain

244 organization revealed by our *SiEsaA*₃₂₈₋₆₈₅ crystal structure suggest that the beta-sheet domain of
245 this protein family is likely the surface exposed region, leading us to speculate that this region of
246 the protein likely serves as the receptor for infecting phage. Indeed, mapping the hypervariable
247 region of PIP proteins onto an *EsaA*-derived homology model of a representative PIP protein
248 from *E. faecalis* V583 indicates that the phage tropism determining region identified by Duerkop
249 et al. likely exists within the beta domain of *EsaA* homologous proteins (Figure S4).

250

251 Discussion

252 Our structure of the extracellular region of *EsaA* has revealed the unique architecture of
253 this enigmatic T7SSb subunit. *EsaA* adopts a novel protein fold that forms highly stable dimers
254 *in vitro* and *in vivo*. The observation that T7SSb subunits form dimers is not without precedent as
255 a recently determined crystal structure of full-length YukC (EssB) from *B. subtilis* found that this
256 T7SSb subunit similarly homodimerizes (Tassinari et al., 2020). EssB/YukC also physically
257 interacts with *EsaA*/YueB suggesting that these two proteins likely function together to facilitate
258 protein secretion across the cell envelope (Ahmed et al., 2018).

259 Though T7SS structural components form dimers in crystals, current evidence indicates
260 that the ultrastructure of an assembled T7SS apparatus involves hexamerization of the apparatus
261 components. For example, the ESX-5 T7SSa from *Mycobacterium xenopi* exhibits six-fold
262 symmetry and is proposed to contain 1:1:1:1 stoichiometry of the four T7SSa apparatus
263 components EccB, EccC, EccD and EccE based on a 13Å negative stain electron microscopy
264 (EM) map (Beckham et al., 2017). More recently, higher resolution cryo-EM structures of the
265 ESX-3 T7SSa from *Mycobacterium smegmatis* have suggested a 1:1:2:1 protomer stoichiometry
266 in which two EccD subunits interact with one subunit each of EccB, EccC, and EccE (Famelis et
267 al., 2019; Poweleit et al., 2019). Though they are not homologues, EccB and *EsaA* are speculated
268 to be functionally equivalent subunits between T7SSa and T7SSb pathways because they both
269 possess large extracellular domains. However, our structure shows that both the overall structure
270 and dimerization mode of *EsaA* is substantially different from that of EccB indicating that these
271 T7SS subunits may have distinct functions. Furthermore, the extracellular region of *EsaA* is cell
272 surface exposed whereas EccB predominantly exists in the mycobacterial periplasm. This
273 observation suggests that additional factors may be involved in T7SSa-dependent effector export
274 across the mycomembrane such as the *EspB* protein or members of the proline-glutamate and
275 proline-proline-glutamate families of proteins (Solomonson et al., 2015; Wang et al., 2020).

276 Ultimately, the structure of an intact T7SSb will be needed for an in-depth comparison between
277 these intriguing protein export machines.

278 The *S. intermedius* T7SSb antibacterial effector TelC exerts toxicity in the inner wall
279 zone (IWZ) by degrading the cell wall precursor lipid II present in the outer leaflet of the plasma
280 membrane (Whitney et al., 2017). We previously used this unique site of action to provide
281 evidence that the T7SSb exports effectors across the plasma membrane and the cell wall in a
282 manner that bypasses the IWZ during transport (Klein et al., 2018). It is now apparent that EsaA,
283 as the only T7SSb apparatus protein with an extended extracellular domain, may well form the
284 conduit that allows for such transport. One of the defining characteristics of Gram-positive
285 Firmicutes bacteria is the 30-50 nm thick peptidoglycan layer, which would likely prevent the
286 diffusion of large LXG effectors from the IWZ to the milieu (Vollmer et al., 2008). Our structure
287 of EsaA is 20 nm long and represents only a portion of the full-length protein. It is therefore
288 within reason that EsaA extends across the entire cell wall to facilitate effector export from the
289 cell. These observations, coupled with the abovementioned propensity for T7SS subunits to
290 adopt six-point symmetry, lead to the tantalizing notion that EsaA dimers might trimerize to
291 form a hexameric tube-shaped assembly. Such a structure would not only enable effector export
292 from T7SSb-containing bacteria but may also facilitate the delivery of effectors into target cells.
293

294 **Experimental Procedures**

295 **Bacterial strains, plasmids and growth conditions**

296 All *S. intermedius* strains were generated from the *S. intermedius* B196 wild-type background. *E.*
297 *coli* XL-1 Blue was used for plasmid maintenance. *E. coli* BL21 (DE3) CodonPlus and B834
298 (DE3) were used for the expression of methionine and selenomethionine containing proteins,
299 respectively. Genomic DNA isolated from *S. intermedius* B196 and *S. gallolyticus* ATCC 43143
300 was used for cloning *SiEsaA* and *SgEsaA*, respectively. A complete list of bacterial strains can
301 be found in Table S1. pET29b and pDL277-derived plasmids were used for protein expression in
302 *E. coli* and *S. intermedius*, respectively. pET29b-derived plasmids were generated by restriction
303 enzyme-based cloning using the NdeI and XhoI restriction endonucleases and T4 DNA ligase.
304 All constructs lacked their native stop codon resulting in the fusion of a vector encoded C-
305 terminal his₆-tag to facilitate protein purification after expression in *E. coli*. Cloning into
306 pDL277 was performed similarly except with the BamHI and Sall restriction endonucleases.
307 Additionally, the P96 promoter sequence from *Streptococcus pneumoniae* was fused upstream of
308 all genes of interest using splicing by overlap extension (SOE) PCR to allow for gene expression
309 in *S. intermedius* (Lo Sapio et al., 2012). All cysteine point mutations were generated by SOE
310 PCR followed by restriction-enzyme based cloning into either pET29b or pDL277 with the
311 abovementioned enzymes. A complete list of plasmids can be found in Table S2. All *E. coli*
312 strains were grown overnight in lysogeny broth at 37°C at 225 rpm in a shaking incubator.
313 Kanamycin (50 µg/mL) was added to the growth media for strains containing pET29b plasmids.
314 All *S. intermedius* strains were grown in Todd Hewitt Broth supplemented with 0.5% yeast
315 extract (THY) in a 37°C stationary 5% CO₂ incubator. To ensure uniform growth rate, all *S.*
316 *intermedius* strains were grown first on THY agar plates for 1-2 days prior to growth in THY
317 broth. Strains harboring pDL277-derived plasmids were grown in media supplemented with
318 spectinomycin (50µg/mL for *S. intermedius* or 100µg/mL for *E. coli*).

319 **DNA manipulation**

320 *S. intermedius* and *S. gallolyticus* genomic DNA was prepared by resuspending cell pellets in
321 InstaGene Matrix (Bio-Rad). Primers were synthesized by Integrated DNA Technology (IDT).
322 Molecular cloning was performed using Q5 polymerase, restriction enzymes, and T4 DNA ligase
323 from New England Biolabs (NEB). Sanger sequencing was performed by Genewiz Incorporated.

324

325 **Transformation of *S. intermedius***

326 *S. intermedius* transformation with either plasmid or linear DNA were performed as previously
327 described (Tomoyasu et al., 2010). In short, overnight cultures were back diluted 1:10 into 2 ml
328 THY broth supplemented with 3 μ L of 10 mg/ml *S. intermedius* competence stimulating peptide
329 (DSRIRMGFDFSKLFGK, synthesized by Genscript) and incubated at 37°C, 5% CO₂ for 2
330 hours. Approximately 100-500ng of plasmid, or linear insert DNA was added and cultures were
331 briefly vortexed before incubating for another 3 hours. 100 μ l of culture was then plated on the
332 appropriate selective media (either 50 μ g/ml spectinomycin, 250 μ g/ml kanamycin, or both).

333 **Gene deletion in *S. intermedius* by allelic replacement**

334 SOE PCR was used generate a pETduet-1 plasmid containing the *kanR* cassette from the
335 pBAV1k-e plasmid under the control of the spectinomycin promoter from pDL277. The
336 spectinomycin promoter-kanamycin resistance cassette was cloned between the 1000 base pairs
337 of DNA that flank the 5' and 3' ends of *esaA* including the first 15 bases of the *esaA* ORF at the
338 end of 5' flank and the last 15 bases of *esaA* at the start of the 3' flank. The final plasmid for
339 allelic replacement was pETduet-1::5'*esaA*flank_SpecPromoter_*kanR*_3'*esaA*flank. This
340 plasmid was then digested with BamHI and NotI and the resulting insert
341 (5'*esaA*flank_SpecPromoter_*kanR*_3'*esaA*flank) was gel extracted (Monarch DNA Gel
342 Extraction Kit, NEB). 100 ng of purified insert was transformed into *S. intermedius* B196 and
343 plated onto THY agar plates supplemented with 250 μ g/ml of kanamycin. PCR was used to
344 confirm deletion of *esaA*.

345 **Secretion assays**

346 Overnight cultures of *S. intermedius* strains were centrifuged at 7600 g, resuspended in 1.6 ml
347 fresh THY broth. These washed cultures were then used to inoculate 5 ml THY broth in 15 ml
348 polypropylene centrifuge tubes to an initial OD of 0.1. Cells were harvested (4000 rpm, 4°C, 15
349 min) when they reached OD₆₀₀ 0.7-0.9 and supernatant fractions were prepared as follows. 3.5
350 ml of supernatant was removed and filtered through a 0.2 μ m membrane to remove remaining
351 cells. Proteins were precipitated at 4°C for 30 minutes by adding 700 μ l of cold 100%
352 trichloroacetic acid (TCA, final concentration 16.7%). Precipitant was collected by
353 centrifugation (swinging-bucket, 4600 rpm, 4°C, 30 min), and washed 3 times with 500 μ l of
354 cold acetone. Precipitant was then air dried in a fume hood for at least 30 minutes before being
355 dissolved in 20 μ l resuspension buffer (50 mM Tris:HCl pH 8.0, 150 mM NaCl, 1X protease

356 cocktail inhibitor). Cell fractions were prepared as follows. Cell pellets were washed with 1 ml
357 PBS, transferred to a 2 ml centrifuge tube, re-pelleted (10,000 g, 4°C, 10 min), decanted and
358 snap frozen at -80°C. Washed pellets were then resuspended in 50 µl of lysis buffer (50 mM
359 Tris:HCl pH 8.0, 150 mM NaCl, 10 mg/ml lysozyme, 1X protease cocktail inhibitor), and
360 incubated at 37°C for half an hour. Cell numbers were matched across samples by diluting cells
361 in PBS based on final culture OD₆₀₀. Matched samples were then prepared for western blotting
362 by mixing 2:1 with 4X SDS-PAGE loading dye (125 mM Tris:HCl pH 6.8, 20% v/v glycerol,
363 0.01% w/v bromophenol blue, 4% v/v BME), heated at 95°C for 10 minutes, and centrifuged
364 (21,000 g, room temperature, 15 minutes).

365 **Antibody generation and western blot analyses**

366 Custom polyclonal antibodies for *S. intermedius* EsaA, EsxA and SodA were generated for this
367 study (Customer's Antigen Polyclonal Antibody Package, Genscript). C-terminally his₆-tagged
368 SiEsaA₄₁₋₈₇₁, EsxA and SodA were purified as described in "Protein purification and expression"
369 except that PBS was used in place of Tris:HCl for all purification buffers. 10 mg of each protein
370 was sent to Genscript for antibody production. Generation of the α-TelC antibody has been
371 described previously (Whitney et al., 2017).

372 With the exception of EsxA, western blot analyses of protein samples were performed using a
373 Tris-glycine gel and buffer system and a standard western blotting protocol. The SDS-PAGE
374 system for EsxA blots required the use of a tris-tricine buffer system, which allows for the
375 electrophoretic separation of low molecular weight proteins. After SDS-PAGE separation,
376 proteins were wet-transferred to 0.45 µm PVDF membranes (80 V for 1 hour, 4°C). Cell and
377 supernatant fractions were analyzed by Western blot using the protein-specific rabbit primary
378 antibodies α-TelC (1:5000 dilution, 1.5 hours), α-EsaA (1:5000, 1 hour), α-EsxA (1:5000, 2
379 hours), α-SodA (1:5000, 30 minutes), α-VSV-G (1:3000, 1.5 hours) and a goat α-rabbit
380 secondary antibody (Sigma, 1:5000, 45 minutes). Clarity Max Western ECL substrate (Bio-Rad)
381 was used for chemiluminescent detection of the secondary antibody and all blots were imaged
382 with a ChemiDoc XRS+ System (Bio-Rad).

383 **NADase activity assay**

384 The consumption of NAD⁺ by *S. intermedius* culture supernatants was assayed as described
385 previously (Whitney et al., 2017). Briefly, culture supernatants taken from mid-log cultures were
386 concentrated 50-fold by spin filtration at 3000 g (10kDa MWCO) and then filtered through a 0.2

387 μm membrane. The samples were then incubated 1:1 with PBS containing 2 mM NAD^+ .
388 Reactions were incubated overnight (approximately 16 hours) at room temperature. 6M NaOH
389 was added to terminate the reaction which was then incubated for 15 minutes in the dark.
390 Fluorescence (ex: 360nm, em: 530nm) was measured using a Synergy 4 Microplate Reader
391 (BioTek Instruments).

392 **Subcellular fractionation by ultracentrifugation**

393 1L *S. intermedius* cultures were grown to $\text{OD}_{600} = 0.8$ and pelleted by centrifugation at 6000 g.
394 Pellets were resuspended in 20 ml of lysis buffer (20 mM Tris:HCl pH 7.5, 150 mM NaCl, 2
395 mg/ml lysozyme), incubated at 37°C for one hour, and sonicated at 30% amplitude for three
396 pulses of 30 seconds each. The insoluble cellular debris was cleared by centrifugation at 39,191
397 g. The resulting supernatant was then centrifuged for two hours at 200,000 g to isolate the
398 membrane fraction. The resulting supernatant (cytosolic fraction) was mixed 1:1 with Laemmli
399 loading buffer. The membrane pellet was washed once with 20 mM Tris:HCl, pH 7.5, 150 mM
400 NaCl, before being resuspended in Laemmli loading buffer. Cytoplasmic and membrane
401 fractions were then analyzed by SDS-PAGE and Western blot.

402 **Membrane topology mapping**

403 The cysteine labelling experiment was adapted from Ruhe et al. (Ruhe et al., 2018). Briefly, 20
404 ml cultures of *S. intermedius* strains were grown to $\text{OD}_{600} = 0.5$ and harvested by centrifugation
405 at 4,000 g for 20 minutes. Cell pellets were then washed three times with PBS to remove any
406 extracellular material. The pellets were resuspended in 35 μl PBS, pH 7.2 and IRDye680LT-
407 maleimide dye (LI-COR Biosciences) was added to cells to a final concentration of 40 μM . The
408 reactions were incubated at room temperature for 30 minutes in a darkroom before being
409 quenched by adding BME to final concentration of 6 mM. Cells were then harvested by
410 centrifugation and washed three times with PBS supplemented with 6 mM BME. Washed pellets
411 were resuspended in SDS-loading dye and boiled for 10 minutes. Samples were run on SDS-
412 PAGE and imaged with a Chemidoc system (Bio-Rad) using a red LED epi-illumination source
413 and a 700nm/50mm band pass filter.

414 **Protein expression and purification**

415 *E. coli* BL21(DE3) CodonPlus strains containing pET29b-derived plasmids were grown to OD_{600}
416 = 0.4 and protein expression was induced with 1 mM IPTG. The induced strains were incubated
417 overnight (approximately 18-20 hours) in a 225 rpm shaking incubator at 18°C after which the

418 cells were collected by centrifugation at 10,000 g. Cell pellets were resuspended in lysis/wash
419 buffer (20 mM Tris-HCl pH 7.5, 300 mM NaCl, 10 mM imidazole) and sonicated four times at
420 30% amplitude for 30 seconds each to lyse cells. Cleared cell lysates were purified by affinity
421 chromatography using a Ni-NTA agarose column. After passing cell lysates over the column, the
422 Ni-NTA resin was washed four times using wash buffer and eluted with wash buffer
423 supplemented with 400 mM imidazole. Protein samples were further purified by size exclusion
424 chromatography using a HiLoad 16/600 Superdex 200 column connected to an AKTA protein
425 purification system (Cytiva).

426 **Crystallization and structure determination**

427 Selenomethionine incorporated *SgEsaA*₂₃₅₋₈₂₉ was concentrated to 10mg/ml by spin filtration
428 using an Amicon Ultra Centrifugal filter unit with a 30kDa pore size (Millipore). Concentrated
429 protein was screened for crystallization with the MCSG Crystallization Suite (Anatrace). Long,
430 slender crystals formed in 0.2M MgCl₂, 0.1M Tris:HCl, pH 7.0, 10% (w/v) PEG 8000, after
431 three weeks. Protein crystallization was optimized around this condition with crystals forming in
432 0.1M Tris:HCl pH 7.0-7.8 and 10-15% (w/v) PEG 8000. Crystals were cryo-protected in similar
433 buffers supplemented with 20% (v/v) ethylene glycol. X-ray data were collected at the Structural
434 Biology Center (SBC) sector 19-ID at the Advanced Photon Source. A total of 290 diffraction
435 images of 0.5° for 0.5 sec/image were collected on a Dectris Pilatus3 X 6M detector with a
436 crystal to detector distance of 540 mm. Data were indexed, integrated, and scaled using the *xia2*
437 system (Winter et al., 2013).

438 The structure of selenomethionine incorporated *SgEsaA*₂₃₅₋₈₂₉ was solved using the Se-SAD
439 method using the AutoSol package in Phenix (Adams et al., 2010). The AutoBuild wizard was
440 subsequently used for model building and the observed electron density allowed model building
441 for residues 330-727 *SgEsaA*₂₃₅₋₈₂₉ with an unmodeled gap between residues 514-554
442 (Terwilliger et al., 2008). Manual adjustments to the model were performed in COOT and model
443 refinement was carried out with Phenix.refine resulting in final R_{work} and R_{free} values of 0.21 and
444 0.26, respectively (Afonine et al., 2012; Emsley and Cowtan, 2004). X-ray data collection and
445 refinement statistics are listed in Table 1.

446 **Homology modeling of *SiEsaA* and PIP**

447 Homology models of *SiEsaA* and *E. faecalis* V583 Phage Infection Protein (PIP) were generated
448 based on our solved structure of *SgEsaA*₂₃₅₋₈₂₉ using the PHYRE² one-to-one threading algorithm

449 (Kelley et al., 2015). *SiEsaA* was modeled with 100% confidence over 325 residues. *E. faecalis*
450 V583 PIP was modeled with 96% confidence over 341 residues.

451 **Sequence alignments and conservation mapping**

452 Protein sequence conservation was mapped onto the structure of *SgEsaA* using the online
453 ConSurf server (Ashkenazy et al., 2016). The multiple sequence alignment used in the
454 calculation was generated as follows. The full-length protein sequence of *SgEsaA* was used as a
455 BLASTp query sequence against the NCBI Reference Protein Sequence database, restricted to
456 the phylum Firmicutes, using otherwise default settings (Altschul et al., 1990). Full length
457 sequences for the top 500 hits were downloaded and sequences shorter than 750 amino acids
458 were filtered out. A multiple sequence alignment using the remaining 434 sequences was
459 generated using Clustal Omega and uploaded with the structure coordinates (Sievers et al.,
460 2011). Dimer interface calculations for *SgEsaA*, including buried surface area and ΔG^i , were
461 performed by uploading structure coordinates to the PDBePISA server (Krissinel and Henrick,
462 2007).

463 **SEC-MALS analysis**

464 Size exclusion chromatography with multi-angle laser static light scattering was performed on
465 *SiEsaA*₃₂₈₋₆₈₅ and *SgEsaA*₃₃₂₋₇₂₅. The proteins were expressed and purified as described above,
466 concentrated to 2 mg/ml by spin filtration and then run on a Superdex 200 column (GE
467 Healthcare). MALS was conducted using a MiniDAWN and Optilab system (Wyatt
468 Technologies). Data was collected and analyzed using the Astra software package (Wyatt
469 Technologies).

470 **Cysteine crosslinking experiments**

471 For in vitro crosslinking experiments, each cysteine mutant was expressed in *E. coli* BL21 (DE3)
472 CodonPlus and the resulting protein was purified by Ni-NTA affinity chromatography. The
473 eluted protein samples were exposed to environmental oxygen for 16 hours to allow for
474 crosslinking to occur. Samples were then mixed 1:1 with Laemmli buffer either containing or
475 lacking β -mercaptoethanol and analyzed by SDS-PAGE and Coomassie staining. The SDS-
476 PAGE gels were imaged using a ChemiDoc MP system (BioRad).
477 *In vivo* cysteine crosslinking was conducted similarly except that a pDL277 plasmid-based
478 system was used to express each cysteine mutant in a *S. intermedius* B196 Δ *esaA* background. *S.*
479 *intermedius* strains were grown to $OD_{600} = 0.8$ and centrifuged at 4000 g. Pellets were

480 resuspended in 200 μ l of lysis buffer (20 mM Tris:HCl, pH 7.5, 150 mM NaCl, 1% *w/v* DDM,
481 10 mg/ml lysozyme) and incubated at 37°C for one hour. Samples were then sonicated three
482 times at 30% amplitude for 15 seconds per pulse. Lysed samples were cleared by centrifugation
483 at 21,130 *g* for 20 minutes. The supernatant was then removed and allowed to sit at room
484 temperature for one hour to allow for crosslinking. Samples were analyzed by Western blot using
485 an α -EsaA primary antibody.
486

487 **Accession numbers**

488 The atomic coordinates and structure factors for the *SgEsaA*₂₃₅₋₈₂₉ crystal structure have been
489 deposited in the Protein Data Bank (<http://wwpdb.org/>) under the PDB code 7JQE.

490

491 **Acknowledgements**

492 The authors would like to thank Nathan Bullen, Shehryar Ahmad and Gerd Prehna for
493 constructive feedback on the manuscript and Madoka Akimoto and Giuseppe Melacini for
494 assistance with SEC-MALS experiments. We sincerely thank the members of the SBC at
495 Argonne National Laboratory for their help with data collection at 19-ID beamline. The use of
496 SBC beamlines at the Advanced Photon Source is supported by the U.S. Department of Energy
497 (DOE) Office of Science and operated for the DOE Office of Science by Argonne National
498 Laboratory under Contract No. DE-AC02-06CH11357. T.A.K. is supported by an Alexander
499 Graham Bell Canada Graduate Scholarship from the Natural Sciences and Engineering Research
500 Council of Canada (NSERC). This work was supported by start-up funds from McMaster
501 University.


502

503 **Author Contributions**

504 T.A.K. and J.C.W. planned the study. All authors contributed to experimental design. T.A.K. and
505 J.C.W. generated strains and plasmids. T.A.K. performed protein expression, purification and
506 crystallization. S.Y.G. and V.S.S. assisted with protein crystallization. T.A.K., D.W.G., Y.K. and
507 J.C.W. solved and analyzed the crystal structure. T.A.K. and D.W.G. performed biochemical
508 experiments. T.A.K., D.W.G., and J.C.W. analyzed the data. T.A.K., D.W.G. and J.C.W. wrote
509 the paper. All authors provided feedback on the manuscript.

510

511




512

513

514 **Figure 1. EsaA is required for WXG-100 and LXG effector export by *S. intermedius*.** (A)
515 Western blot analysis of the cell and supernatant fractions of the indicated *S. intermedius* B196
516 strains. EsxA and TelC belong to the WXG-100 and LXG families of T7SSb effectors,
517 respectively. The Δ essC strain is used as a secretion deficient control. Superoxide dismutase A
518 (SodA) is used as a cell lysis control. (B) Supernatant NADase activity, indicative of T7SSb-
519 dependent TelB secretion, in cultures of the indicated *S. intermedius* B196 strains. This assay
520 was done in triplicate and all values were calculated as a fraction of NAD⁺ turnover compared to
521 purified NADase Tse6 (Whitney et al., 2015). The data displayed represent three independent
522 replicates. Error bars reflect standard error of the mean (SEM).

523

524
525
526
527




528
529

530 **Figure 2. EsA possesses a large extracellular domain.** (A) EsA fractionates with *S.*
531 *intermedius* membranes. TipC and SodA are used as membrane and cytoplasmic controls,
532 respectively. Proteins contain a C-terminal VSV-G tag and were detected by western blot using
533 an α -VSV-G (α -V) primary antibody. (B) Predicted EsA membrane topology depicting the
534 location of each cysteine substitution site. Green star denotes the native cysteine residue present
535 in EsA whereas blue stars indicate cysteine mutations generated for topology mapping. (C)
536 EsA cysteine mutants are expressed and secrete TelC at levels similar to wild-type *S.*
537 *intermedius*. (D) Cysteine mutations in the predicted extracellular domain of EsA are accessible
538 to a cysteine-reactive maleimide dye but those located near the N- and C-termini are not. EsA
539 migrates slightly above the 100kDa marker as indicated.

540


541



542
 543 **Figure 3. The extracellular domain of *SgEsaA* adopts an arrow-shaped structure.**
 544 (A) Domain architecture of *S. intermedius* B196 *EsaA* (*SiEsaA*) and *S. gallolyticus* ATCC 43143
 545 *EsaA* (*SgEsaA*) depicting the chymotrypsin-stable fragment of *SiEsaA*, the crystallized fragment
 546 of *SgEsaA* and the regions of *SgEsaA* for which interpretable electron density was observed in

547 the crystal structure. (B) Topology diagram depicting the secondary structure elements
548 comprising *SgEsaA*₂₃₅₋₈₂₉. Blue and green coloring is used to illustrate the ‘there and back again’
549 topology of the protein. (C) Pipes and planks model of *SgEsaA*₂₃₅₋₈₂₉ shown from two opposing
550 views. Alpha helices and beta strands are denoted by tubes and arrows, respectively. The N- and
551 C-termini are depicted on the left-hand model. (D) *SgEsaA*₂₃₅₋₈₂₉ dimers form an elongated
552 structure. Red and blue ribbon coloring is used to differentiate each monomer within the dimer.
553 (E) Surface representation of an *SgEsaA*₂₃₅₋₈₂₉ dimer shown from orthogonal viewpoints. Yellow
554 coloring is used to highlight the buried surface area between *SgEsaA*₂₃₅₋₈₂₉ protomers. (F)
555 Surface representation of an *SgEsaA*₂₃₅₋₈₂₉ dimer depicting residue-specific sequence
556 conservation among *EsaA* homologous proteins. Details of the sequences used for conservation
557 analysis can be found in Experimental Procedures. Model was generated using the ConSurf
558 server (Ashkenazy et al., 2016).
559

560



561

562

563 **Figure 4. EsA forms dimers *in vitro* and *in vivo*.** (A-B) SEC-MALS analysis of *SgEsaA*₃₃₂₋₇₂₅

564 (A) and *SiEsaA*₃₂₈₋₆₈₅ (B). Relative light scattering is plotted in blue and molecular weight is

565 plotted in orange. The calculated molecular weights of the dimer peaks for both proteins are

566 indicated. (C) Structure of *SgEsaA*₃₃₂₋₇₂₅ depicting the cysteine mutations chosen for cross-

567 linking experiments. *SgEsaA*₃₃₂₋₇₂₅ protomers are depicted as blue and red ribbons with the

568 hypothetical cysteine mutations shown as sticks. The identities of the residues normally found in

569 these positions are indicated for both *SgEsaA* (left) and *SiEsaA* (right). (D-E) Coomassie blue-

570 stained gel demonstrating cysteine crosslinking for each of the purified *SgEsaA*₃₃₂₋₇₂₅ (D) and

571 *SiEsaA*₃₂₈₋₆₈₅ (E) cysteine variants. (F) Western blot analysis of *S. intermedius* B196 Δ *esaA*

572 strains expressing wild-type EsA or each of the indicated EsA cysteine variants. BME, β -

573 mercaptoethanol.

574 **Table 1: X-ray data collection and refinement statistics**

SgEsa²³⁴⁻⁸²⁹ (selenomethionine)	
Data Collection	
Wavelength (Å)	0.9792
Space group	C222 ₁
Cell dimensions	
<i>a, b, c</i> (Å)	74.4, 248.5, 81.0
<i>α, β, γ</i> (°)	90.0, 90.0, 90.0
Resolution (Å)	55.34-2.40 (2.44-2.40) ^a
Total no. of reflections	139995
Total no. of unique reflections	29568
<i>R</i> _{merge} (%) ^b	11.6 (81.0) ^a
<i>I</i> / <i>σI</i>	6.1 (1.0) ^a
Completeness (%)	98.7 (89.3) ^a
Redundancy	4.7 (2.8) ^a
<i>CC</i> _{1/2}	0.99 (0.51) ^a
Refinement	
<i>R</i> _{work} / <i>R</i> _{free} (%) ^c	21.46/26.16
No. atoms	
Protein	2947
Water	28
Average B-factors (Å ²)	
Protein	77.69
Water	58.79
Rms deviations	
Bond lengths (Å)	0.002
Bond angles (°)	0.427
Ramachandran plot (%) ^d	
Total favored	98.3
Total allowed	1.7
Coordinate error (Å) ^e	0.34

575

576 ^aValues in parentheses correspond to the highest resolution shell.

577 ^b $R_{\text{merge}} = \frac{\sum \sum |I(k) - \langle I \rangle|}{\sum I(k)}$ where *I*(*k*) and *<I>* represent the diffraction intensity values of the
578 individual measurements and the corresponding mean values. The summation is over all unique
579 measurements.

580 ^c $R_{\text{work}} = \frac{\sum ||F_{\text{obs}}| - k|F_{\text{calc}}||}{\sum |F_{\text{obs}}|}$ where *F*_{obs} and *F*_{calc} are the observed and calculated structure
581 factors, respectively. *R*_{free} is the sum extended over a subset of reflections (5%) excluded from all
582 stages of the refinement.

583 ^dAs calculated using MOLPROBITY (Chen et al., 2010).

584 ^eMaximum-Likelihood Based Coordinate Error, as determined by PHENIX (Adams et al., 2010).

585

586

587

588 **References**

- 589 Abdallah, A.M., Gey van Pittius, N.C., Champion, P.A., Cox, J., Luirink, J., Vandembroucke-
590 Grauls, C.M., Appelmelk, B.J., and Bitter, W. (2007). Type VII secretion--mycobacteria show
591 the way. *Nature reviews. Microbiology* 5, 883-891.
- 592 Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J.,
593 Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., *et al.* (2010). PHENIX: a comprehensive
594 Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr*
595 66, 213-221.
- 596 Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., Headd, J.J., Moriarty, N.W., Mustyakimov,
597 M., Terwilliger, T.C., Urzhumtsev, A., Zwart, P.H., and Adams, P.D. (2012). Towards
598 automated crystallographic structure refinement with phenix.refine. *Acta crystallographica.*
599 Section D, Biological crystallography 68, 352-367.
- 600 Ahmed, M.M., Aboshanab, K.M., Ragab, Y.M., Missiakas, D.M., and Aly, K.A. (2018). The
601 transmembrane domain of the Staphylococcus aureus ESAT-6 component EssB mediates
602 interaction with the integral membrane protein EsaA, facilitating partially regulated secretion in
603 a heterologous host. *Archives of microbiology* 200, 1075-1086.
- 604 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local
605 alignment search tool. *Journal of molecular biology* 215, 403-410.
- 606 Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N. (2016).
607 ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in
608 macromolecules. *Nucleic acids research* 44, W344-350.
- 609 Aspiras, M.B., Kazmerzak, K.M., Kolenbrander, P.E., McNab, R., Hardegen, N., and Jenkinson,
610 H.F. (2000). Expression of green fluorescent protein in Streptococcus gordonii DL1 and its use
611 as a species-specific marker in coadhesion with Streptococcus oralis 34 in saliva-conditioned
612 biofilms in vitro. *Applied and environmental microbiology* 66, 4074-4083.
- 613 Beckham, K.S., Ciccarelli, L., Bunduc, C.M., Mertens, H.D., Ummels, R., Lugmayr, W., Mayr,
614 J., Rettel, M., Savitski, M.M., Svergun, D.I., *et al.* (2017). Structure of the mycobacterial ESX-5
615 type VII secretion system membrane complex by single-particle analysis. *Nat Microbiol* 2,
616 17047.
- 617 Burts, M.L., Williams, W.A., DeBord, K., and Missiakas, D.M. (2005). EsxA and EsxB are
618 secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus
619 aureus infections. *Proceedings of the National Academy of Sciences of the United States of*
620 *America* 102, 1169-1174.
- 621 Cao, Z., Casabona, M.G., Kneuper, H., Chalmers, J.D., and Palmer, T. (2016). The type VII
622 secretion system of Staphylococcus aureus secretes a nuclease toxin that targets competitor
623 bacteria. *Nat Microbiol* 2, 16183.
- 624 Chatterjee, A., Willett, J.L., Dunny, G.M., and Duerkop, B.A. (2020). Phage infection mediates
625 inhibition of bystander bacteria. *BioRxiv* (doi: <https://doi.org/10.1101/2020.05.11.077669>).
- 626 Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J.,
627 Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom structure
628 validation for macromolecular crystallography. *Acta crystallographica. Section D, Biological*
629 *crystallography* 66, 12-21.
- 630 Dreisbach, A., Hempel, K., Buist, G., Hecker, M., Becher, D., and van Dijl, J.M. (2010).
631 Profiling the surfacome of Staphylococcus aureus. *Proteomics* 10, 3082-3096.
- 632 Duerkop, B.A., Huo, W., Bhardwaj, P., Palmer, K.L., and Hooper, L.V. (2016). Molecular Basis
633 for Lytic Bacteriophage Resistance in Enterococci. *mBio* 7.

- 634 Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta*
635 *crystallographica. Section D, Biological crystallography* *60*, 2126-2132.
- 636 Famelis, N., Rivera-Calzada, A., Degliesposti, G., Wingender, M., Mietrach, N., Skehel, J.M.,
637 Fernandez-Leiro, R., Bottcher, B., Schlosser, A., Llorca, O., *et al.* (2019). Architecture of the
638 mycobacterial type VII secretion system. *Nature* *576*, 321-325.
- 639 Gao, L.Y., Guo, S., McLaughlin, B., Morisaki, H., Engel, J.N., and Brown, E.J. (2004). A
640 mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading
641 and ESAT-6 secretion. *Molecular microbiology* *53*, 1677-1693.
- 642 Hasegawa, N., Sekizuka, T., Sugi, Y., Kawakami, N., Ogasawara, Y., Kato, K., Yamashita, A.,
643 Takeuchi, F., and Kuroda, M. (2017). Characterization of the Pathogenicity of *Streptococcus*
644 *intermedius* TYG1620 Isolated from a Human Brain Abscess Based on the Complete Genome
645 Sequence with Transcriptome Analysis and Transposon Mutagenesis in a Murine Subcutaneous
646 Abscess Model. *Infection and immunity* *85*.
- 647 Holm, L. (2020). DALI and the persistence of protein shape. *Protein science : a publication of*
648 *the Protein Society* *29*, 128-140.
- 649 Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J. (2015). The Phyre2 web
650 portal for protein modeling, prediction and analysis. *Nature protocols* *10*, 845-858.
- 651 Klein, T.A., Ahmad, S., and Whitney, J.C. (2020). Contact-Dependent Interbacterial Antagonism
652 Mediated by Protein Secretion Machines. *Trends in microbiology* *28*, 387-400.
- 653 Klein, T.A., Pazos, M., Surette, M.G., Vollmer, W., and Whitney, J.C. (2018). Molecular Basis
654 for Immunity Protein Recognition of a Type VII Secretion System Exported Antibacterial Toxin.
655 *Journal of molecular biology* *430*, 4344-4358.
- 656 Kneuper, H., Cao, Z.P., Twomey, K.B., Zoltner, M., Jager, F., Cargill, J.S., Chalmers, J., van der
657 Kooi-Pol, M.M., van Dijl, J.M., Ryan, R.P., *et al.* (2014). Heterogeneity in *ess* transcriptional
658 organization and variable contribution of the *Ess*/Type VII protein secretion system to virulence
659 across closely related *Staphylococcus aureus* strains. *Molecular microbiology* *93*, 928-943.
- 660 Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline
661 state. *Journal of molecular biology* *372*, 774-797.
- 662 Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E.L. (2001). Predicting
663 transmembrane protein topology with a hidden Markov model: application to complete genomes.
664 *Journal of molecular biology* *305*, 567-580.
- 665 Lo Sapio, M., Hilleringmann, M., Barocchi, M.A., and Moschioni, M. (2012). A novel strategy
666 to over-express and purify homologous proteins from *Streptococcus pneumoniae*. *Journal of*
667 *biotechnology* *157*, 279-286.
- 668 Mietrach, N., Schlosser, A., and Geibel, S. (2019). An extracellular domain of the *EsaA*
669 membrane component of the type VIIb secretion system: expression, purification and
670 crystallization. *Acta Crystallogr F Struct Biol Commun* *75*, 725-730.
- 671 Ohr, R.J., Anderson, M., Shi, M., Schneewind, O., and Missiakas, D. (2017). *EssD*, a Nuclease
672 Effector of the *Staphylococcus aureus* *ESS* Pathway. *Journal of bacteriology* *199*.
- 673 Olson, A.B., Kent, H., Sibley, C.D., Grinwis, M.E., Mabon, P., Ouellette, C., Tyson, S., Graham,
674 M., Tyler, S.D., Van Domselaar, G., *et al.* (2013). Phylogenetic relationship and virulence
675 inference of *Streptococcus Anginosus* Group: curated annotation and whole-genome
676 comparative analysis support distinct species designation. *BMC genomics* *14*, 895.
- 677 Poweleit, N., Czudnochowski, N., Nakagawa, R., Trinidad, D.D., Murphy, K.C., Sasseti, C.M.,
678 and Rosenberg, O.S. (2019). The structure of the endogenous *ESX-3* secretion system. *eLife* *8*.

679 Rosenberg, O.S., Dovala, D., Li, X., Connolly, L., Bendebury, A., Finer-Moore, J., Holton, J.,
680 Cheng, Y., Stroud, R.M., and Cox, J.S. (2015). Substrates Control Multimerization and
681 Activation of the Multi-Domain ATPase Motor of Type VII Secretion. *Cell* *161*, 501-512.
682 Ruhe, Z.C., Subramanian, P., Song, K., Nguyen, J.Y., Stevens, T.A., Low, D.A., Jensen, G.J.,
683 and Hayes, C.S. (2018). Programmed Secretion Arrest and Receptor-Triggered Toxin Export
684 during Antibacterial Contact-Dependent Growth Inhibition. *Cell* *175*, 921-933 e914.
685 Sao-Jose, C., Baptista, C., and Santos, M.A. (2004). Bacillus subtilis operon encoding a
686 membrane receptor for bacteriophage SPP1. *Journal of bacteriology* *186*, 8337-8346.
687 Sao-Jose, C., Lhuillier, S., Lurz, R., Melki, R., Lepault, J., Santos, M.A., and Tavares, P. (2006).
688 The ectodomain of the viral receptor YueB forms a fiber that triggers ejection of bacteriophage
689 SPP1 DNA. *The Journal of biological chemistry* *281*, 11464-11470.
690 Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H.,
691 Remmert, M., Soding, J., *et al.* (2011). Fast, scalable generation of high-quality protein multiple
692 sequence alignments using Clustal Omega. *Mol Syst Biol* *7*, 539.
693 Solomonson, M., Setiaputra, D., Makepeace, K.A.T., Lameignere, E., Petrotchenko, E.V.,
694 Conrady, D.G., Bergeron, J.R., Vuckovic, M., DiMaio, F., Borchers, C.H., *et al.* (2015).
695 Structure of EspB from the ESX-1 type VII secretion system and insights into its export
696 mechanism. *Structure* *23*, 571-583.
697 Stanger, F.V., de Beer, T.A.P., Dranow, D.M., Schirmer, T., Phan, I., and Dehio, C. (2017). The
698 BID Domain of Type IV Secretion Substrates Forms a Conserved Four-Helix Bundle Topped
699 with a Hook. *Structure* *25*, 203-211.
700 Tassinari, M., Doan, T., Bellinzoni, M., Chabalier, M., Ben-Assaya, M., Martinez, M., Gaday,
701 Q., Alzari, P.M., Cascales, E., Fronzes, R., and Gubellini, F. (2020). Central role and structure of
702 the membrane pseudokinase YukC in the antibacterial Bacillus subtilis Type VIIb Secretion
703 System. *BioRxiv* (doi: <https://doi.org/10.1101/2020.05.09.085852>).
704 Terwilliger, T.C., Grosse-Kunstleve, R.W., Afonine, P.V., Moriarty, N.W., Zwart, P.H., Hung,
705 L.W., Read, R.J., and Adams, P.D. (2008). Iterative model building, structure refinement and
706 density modification with the PHENIX AutoBuild wizard. *Acta crystallographica. Section D,*
707 *Biological crystallography* *64*, 61-69.
708 Tomoyasu, T., Tabata, A., Hiroshima, R., Imaki, H., Masuda, S., Whiley, R.A., Aduse-Opoku,
709 J., Kikuchi, K., Hiramatsu, K., and Nagamune, H. (2010). Role of catabolite control protein A in
710 the regulation of intermedilysin production by Streptococcus intermedius. *Infection and*
711 *immunity* *78*, 4012-4021.
712 Ulhuq, F.R., Gomes, M.C., Duggan, G.M., Guo, M., Mendonca, C., Buchanan, G., Chalmers,
713 J.D., Cao, Z., Kneuper, H., Murdoch, S., *et al.* (2020). A membrane-depolarizing toxin substrate
714 of the Staphylococcus aureus type VII secretion system mediates intraspecies competition.
715 *Proceedings of the National Academy of Sciences of the United States of America.*
716 Vollmer, W., Blanot, D., and de Pedro, M.A. (2008). Peptidoglycan structure and architecture.
717 *FEMS microbiology reviews* *32*, 149-167.
718 Wang, Q., Boshoff, H.I.M., Harrison, J.R., Ray, P.C., Green, S.R., Wyatt, P.G., and Barry, C.E.,
719 3rd. (2020). PE/PPE proteins mediate nutrient transport across the outer membrane of
720 Mycobacterium tuberculosis. *Science* *367*, 1147-1151.
721 Whitney, J.C., Peterson, S.B., Kim, J., Pazos, M., Verster, A.J., Radey, M.C., Kulasekara, H.D.,
722 Ching, M.Q., Bullen, N.P., Bryant, D., *et al.* (2017). A broadly distributed toxin family mediates
723 contact-dependent antagonism between gram-positive bacteria. *eLife* *6*.

724 Whitney, J.C., Quentin, D., Sawai, S., LeRoux, M., Harding, B.N., Ledvina, H.E., Tran, B.Q.,
725 Robinson, H., Goo, Y.A., Goodlett, D.R., *et al.* (2015). An interbacterial NAD(P)(+)
726 glycohydrolase toxin requires elongation factor Tu for delivery to target cells. *Cell* *163*, 607-619.
727 Winter, G., Lobley, C.M., and Prince, S.M. (2013). Decision making in xia2. *Acta*
728 *crystallographica. Section D, Biological crystallography* *69*, 1260-1273.
729
730

731 **Supplemental Data**

732

733 **Structure of the extracellular region of the bacterial type VIIb secretion**
734 **system subunit EsaA**

735

736 Timothy A. Klein,^{1,2} Dirk W. Grebenc,^{1,2} Shil Y. Gandhi,^{1,2} Vraj S. Shah,^{1,2} Youngchang Kim,³
737 and John C. Whitney^{1,2,4*}

738

739

740

741 ¹Michael DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON,
742 L8S 4K1, Canada

743 ²Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON,
744 L8S 4K1, Canada

745 ³Structural Biology Center, X-ray Science, Argonne National Laboratory, Argonne, Illinois,
746 USA

747 ⁴David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, ON, L8S 4K1,
748 Canada

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766 * To whom correspondence should be addressed: J.C.W.

767 Email – jwhitney@mcmaster.ca

768 Telephone – (+1) 905-525-9140

769


770 **Running title:** Structure of EsaA

771

772

773

774




775

776

777 **Supplementary Figure 1. Schematic depicting the two common predicted membrane**
778 **topologies of EsaA.** (A-B) EsaA proteins typically have one N-terminal and one C-terminal
779 TMD (A) or one N-terminal and five C-terminal TMDs (B). TMDs as predicted by TMHMM are
780 depicted in red (Krogh et al., 2001). Several representative strains of Firmicutes bacteria are
781 listed for each topology.

782

783
784
785
786
787
788
789
790
791



792
793
794
795
796
797
798
799
800

Supplementary Figure 2. Digestion of *SiEsaA*₄₁₋₈₇₁ with chymotrypsin results in a stable

truncation of approximately 55kDa. A 1:100 (w/w) chymotrypsin: *SiEsaA*₄₁₋₈₇₁ digestion was conducted over one hour with samples being taken every 20 minutes. The (-) condition indicates untreated *SiEsaA*₄₁₋₈₇₁. *SiEsaA*₄₁₋₈₇₁ has a predicted molecular weight of 92.5kDa and the amino acid sequence of the 55kDa truncation of *SiEsaA*₄₁₋₈₇₁ was confirmed by liquid chromatography-tandem mass spectrometry.


801
802
803
804



805
806 **Supplementary Figure 3. The BID domain of Bep9 from *Bartonella clarridgeiae* resembles**
807 **the AD-I domain of SgEsaA₂₃₅₋₈₂₉.** Bep9 (PDB code 4YK2) is the highest scoring structural
808 homologue for SgEsaA₂₃₅₋₈₂₉ as determined by DALILITE (Z-score, 8.5; C α root mean squared
809 deviation of 3.5Å over 100 aligned residues). The structures of Bep9 (orange) and SgEsaA₂₃₅₋₈₂₉
810 (blue) were superimposed using UCSF Chimera.

811
812

813
814
815
816
817



E. faecalis V583 Phage Infection Protein (PIP)

818
819
820
821
822
823
824
825

Supplementary Figure 4. The structure of *SgEsaA*₂₃₅₋₈₂₉ allows for homology modelling of *E. faecalis* V583 PIP. (A) Ribbon and (B) surface diagrams of the structure of the *E. faecalis* V583 PIP protein were generated by the one-to-one threading algorithm of Phyre² (Kelley et al., 2015). The phage tropism region, coloured pink and purple, encompasses the BDs and a short segment of the AD-II domains of the *SgEsaA*₂₃₅₋₈₂₉ homodimer.

826 **Table S1: Bacterial strains used in this study**

Organism	Genotype	Description	Reference
<i>S. intermedius</i> B196	Wild-type		(Olson et al., 2013)
	Δ SIR_0175::kan ^R	<i>essC</i> deletion strain	(Klein et al., 2018)
	Δ SIR_0176::kan ^R	<i>esaA</i> deletion strain	This study
<i>S. gallolyticus</i> ATCC 43143	Wild-type		
<i>E. coli</i> XL-1 Blue	<i>recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F' proAB lacI^s Z Δ M15 Tn10 (Tet^R)]</i>	Cloning strain	Agilent
<i>E. coli</i> BL21 (DE3) CodonPlus	F ⁻ <i>ompT gal dcm lon hsdS_B(r_B⁻ m_B⁻) λ(DE3) pLysS(Cm^R)</i>	Protein expression strain	Novagen
<i>E. coli</i> B834 (DE3)	F ⁻ <i>ompT hsdS_B(r_B⁻ m_B⁻) λ(DE3) gal dcm met</i>	Methionine auxotroph	Novagen

827

828

829 **Table S2: Plasmids used in this study**

Plasmid	Relevant features	Reference
pDL277	<i>E. coli</i> - <i>Streptococcus</i> shuttle vector, SpecR	(Aspiras et al., 2000)
pDL277::p96_esaA_VSV-G	Wild-type EsaA expression vector for <i>S. intermedius</i>	This study
pDL277::p96_esaA_V8C_VSV-G	EsaA V8C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_V150C_VSV-G	EsaA V150C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_F302C_VSV-G	EsaA VF302C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_S454C_VSV-G	EsaA S454C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_S605C_VSV-G	EsaA S605C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_V762C_VSV-G	EsaA V762C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_F909C_VSV-G	EsaA F909C expression vector for <i>S. intermedius</i> topology experiment	This study
pDL277::p96_esaA_N586C_VSV-G	EsaA N586C expression vector for <i>S. intermedius in vivo</i> crosslinking experiment	This study
pDL277::p96_esaA_T612C_VSV-G	EsaA T612C expression vector for <i>S. intermedius in vivo</i> crosslinking experiment	This study
pDL277::p96_esaA_L644C_VSV-G	EsaA L644C expression vector for <i>S. intermedius in vivo</i> crosslinking experiment	This study
pETDuet-1	Co-expression vector with <i>lacI</i> , T7 promoter, N-term His6 in MCS1, AmpR	Novagen
pETDuet-1::5'esaAflank_Pspec_KanR_3'esaAflank	Plasmid containing <i>S. intermedius esaA</i> knockout construct for allelic replacement	This study
pET29b	Expression vector with <i>lacI</i> , T7 promoter, C-term His6, KanR	Novagen
pET29b::SiesaA_41-871	Expression vector for the soluble region of <i>SiEsaA</i>	This study
pET29b::SiesaA_234-790	Expression vector for <i>SiEsaA</i>	This study

pET29b:: <i>SiesaA_328-685</i>	truncation based on chymotrypsin digestion Expression vector for <i>SiEsaA</i>	This study
pET29b:: <i>SiesaA_328-685_N586C</i>	truncation based on the crystal structure of <i>SgEsaA</i> Expression vector for <i>SiEsaA</i>	This study
pET29b:: <i>SiesaA_328-685_T612C</i>	truncation based on the crystal structure of <i>SgEsaA</i> with N586C mutation Expression vector for <i>SiEsaA</i>	This study
pET29b:: <i>SiesaA_328-685_L644C</i>	truncation based on the crystal structure of <i>SgEsaA</i> with T612C mutation Expression vector for <i>SiEsaA</i>	This study
pET29b:: <i>SgesaA_235-829</i>	truncation based on the crystal structure of <i>SgEsaA</i> with L644C mutation Expression vector for the <i>SgEsaA</i>	This study
pET29b:: <i>SgesaA_332-725</i>	truncation based on the crystal structure of <i>SgEsaA</i> with L644C mutation Expression vector for the <i>SgEsaA</i> chymotrypsin truncation	This study
pET29b:: <i>SgesaA_332-725_T628C</i>	truncation based on the solved structure of <i>SgEsaA</i> Expression vector for the <i>SgEsaA</i>	This study
pET29b:: <i>SgesaA_332-725_A654C</i>	truncation based on the solved structure of <i>SgEsaA</i> with T628C mutation Expression vector for the <i>SgEsaA</i>	This study
pET29b:: <i>SgesaA_332-725_L688C</i>	truncation based on the solved structure of <i>SgEsaA</i> with T628C mutation Expression vector for the <i>SgEsaA</i>	This study